New inhaled drug aims to stop lung infections in vulnerable cancer patients
Disease control
Recruiting now
This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers (like leukemia or lymphoma) or who have had a stem cell transplant and caught a lung virus (PIV, hMPV, or RSV). The goal is to see if PUL-042 can prevent or reduce serious lung complicat…
Phase: PHASE2 • Sponsor: Pulmotect, Inc. • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC